var data={"title":"Heparin (unfractionated): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Heparin (unfractionated): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6307?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=heparin-unfractionated-patient-drug-information\" class=\"drug drug_patient\">see &quot;Heparin (unfractionated): Patient drug information&quot;</a> and <a href=\"topic.htm?path=heparin-unfractionated-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Heparin (unfractionated): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178752\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Hep Flush-10 [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178753\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Heparin Leo;</li>\n      <li>Heparin Lock Flush;</li>\n      <li>Heparin Sodium Injection, USP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178797\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticoagulant;</li>\n      <li>\n        Anticoagulant, Heparin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178757\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Many concentrations of heparin are available ranging from 1 unit/mL to 20,000 units/mL. Carefully examine each prefilled syringe or vial prior to use ensuring that the correct concentration is chosen. Heparin lock flush solution is intended only to maintain patency of IV devices and is not to be used for anticoagulant therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute coronary syndromes (off-label use):</b> IV infusion (weight-based dosing per institutional nomogram recommended):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>STEMI:</i> Adjunct to fibrinolysis (full-dose alteplase, reteplase, or tenecteplase): Initial bolus of 60 units/kg (maximum: 4,000 units), then 12 units/kg/hour (maximum: 1,000 units/hour) as continuous infusion. Adjust to target aPTT of 1.5 to 2 times control (approximately 50 to 70 seconds). Continue for a minimum of 48 hours, and preferably for the duration of hospitalization (up to 8 days) or until revascularization (if performed) (ACCF/AHA [O&rsquo;Gara 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>NSTE-ACS:</i> Initial bolus of 60 units/kg (maximum: 4,000 units), followed by an initial infusion of 12 units/kg/hour (maximum: 1,000 units/hour). Adjust to target aPTT of 1.5 to 2 times control (approximately 50 to 70 seconds). Recommended duration is 48 hours or until percutaneous coronary intervention (PCI) is performed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> If PCI is performed while patient on fondaparinux, 85 units/kg of heparin (60 units/kg if a GP IIb/IIIa inhibitor [eg, abciximab, eptifibatide, tirofiban] is used concomitantly) should be given immediately before PCI with subsequent heparin dosing based on the target activated clotting time (AHA/ACC [Amsterdam 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anticoagulation (Intermittent administration):</b> IV: Initial: 10,000 units, then 50 to 70 units/kg (5,000 to 10,000 units) every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Atrial fibrillation (off-label use):</b> Guidelines pertaining to peri-cardioversion use (ACCP [You 2012]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients with atrial fibrillation (for more than 48 hours or unknown duration) undergoing cardioversion</i>: IV heparin to maintain an aPTT prolongation that corresponds to plasma heparin levels of 0.3 to 0.7 units/mL anti-Xa activity started at the time of transesophageal echocardiography (TEE) is recommended with cardioversion performed within 24 hours of the TEE if no thrombus is seen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients with atrial fibrillation (for 48 hours or less) undergoing cardioversion:</i> Cardioversion may be performed without prolonged anticoagulation. However, anticoagulation with IV heparin to maintain an aPTT prolongation that corresponds to plasma heparin levels of 0.3 to 0.7 units/mL anti-Xa activity should be started at presentation in patients with no contraindications to anticoagulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Emergency cardioversion in hemodynamically unstable patient:</i> Cardioversion may be performed without prolonged anticoagulation. Anticoagulation with IV heparin to maintain an aPTT prolongation that corresponds to plasma heparin levels of 0.3 to 0.7 units/mL anti-Xa activity should be started prior to cardioversion in patients with no contraindications to anticoagulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cardiothoracic surgery (cardiopulmonary bypass):</b> IV: Initial: 300 to 400 units/kg prior to arterial or venous cannulation; titrate to ACT. Cardiopulmonary bypass may be initiated once ACT is at least 400 seconds; measure ACT every 30 minutes and administer additional heparin as necessary (Kincaid 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Interstitial cystitis (bladder pain syndrome) (off-label use):</b> Intravesical: <b>Note:</b> Various dosage regimens of heparin (20,000 to 50,000 units) alone or with alkalinized lidocaine (1% to 4%) have been used. When lidocaine and heparin are mixed, there is a risk of precipitation if proper alkalinization does not occur. Lidocaine stability and pH should be determined after the components have been mixed, prior to administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Single-dose regimen:</i> Instill the combination of 50,000 units of heparin, lidocaine 200 mg, and sodium bicarbonate 420 mg in 15 mL of sterile water into the bladder via catheter and allow to dwell for 30 minutes before draining (Parsons 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Once-weekly dosing regimen:</i> Instill the combination of 20,000 units of heparin, lidocaine 4% (5 mL), and sodium bicarbonate 7% (25 mL) into an empty bladder via catheter once weekly for 12 weeks and allow to dwell for 30 minutes before draining (Nomiya 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Twice-weekly dosing regimen:</i> Instill 25,000 units of heparin (diluted with 5 mL of sterile water) into bladder via catheter twice weekly for 3 months (Kuo 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Maintenance of catheter patency (continuous infusion):</b> Using heparin 2 unit/mL large volume IV solutions, may administer at an infusion rate of 3 mL/hour (equivalent to 6 units/hour); however, rate of infusion dependent upon age, weight, clinical condition of patient, and procedure being employed. Do not use as a &quot;catheter lock flush&quot;.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Maintenance of line patency (line flushing):</b> When using daily flushes of heparin to maintain patency of single and double lumen central catheters, 10 units/mL is commonly used for younger infants (eg, &lt;10 kg) while 100 units/mL is used for older infants, children, and adults. Capped PVC catheters and peripheral heparin locks require flushing more frequently (eg, every 6 to 8 hours). Volume of heparin flush is usually similar to volume of catheter (or slightly greater). Additional flushes should be given when stagnant blood is observed in catheter, after catheter is used for drug or blood administration, and after blood withdrawal from catheter.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parenteral nutrition:</b> Addition of heparin (0.5 to 3 unit/mL) to peripheral and central parenteral nutrition has not been shown to decrease catheter-related thrombosis. The final concentration of heparin used for TPN solutions may need to be decreased to 0.5 units/mL in small infants receiving larger amounts of volume in order to avoid approaching therapeutic amounts. Arterial lines are heparinized with a final concentration of 1 unit/mL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Percutaneous coronary intervention (off-label use; Levine 2011):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">No prior anticoagulant therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>If no GPIIb/IIIa inhibitor use planned:</i> Initial bolus of 70 to 100 units/kg (target ACT 250 to 300 seconds for HemoTec&reg;, 300 to 350 seconds for Hemochron&reg;)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>If planning GPIIb/IIIa inhibitor use:</i> Initial bolus of 50 to 70 units/kg (target ACT 200 to 250 seconds regardless of device)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prior anticoagulant therapy:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>If no GPIIb/IIIa inhibitor use planned:</i> Additional heparin as needed (eg, 2,000 to 5,000 units) (target ACT 250 to 300 seconds for HemoTec&reg;, 300 to 350 seconds for Hemochron&reg;)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>If planning GPIIb/IIIa inhibitor use:</i> Additional heparin as needed (eg, 2,000 to 5,000 units) (target ACT 200 to 250 seconds regardless of device)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thromboprophylaxis (low-dose heparin):</b> SubQ: 5,000 units every 8 to 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Duration of therapy and specific dosing for certain populations<i>: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Acute illness in hospitalized cancer patients: </i>SubQ: 5,000 units every 8 hours (a frequency of every 12 hours has been used but appears to be less effective); recommended duration of therapy is length of hospital stay or until fully ambulatory (Lyman 2013; Lyman 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Major surgery in cancer patients: </i>SubQ: 5,000 units 2 to 4 hours preoperative and 5,000 units every 8 hours thereafter (a frequency of every 12 hours has been used but appears to be less effective); continue therapy for at least 7 to 10 days. Prolonged treatment up to 4 weeks should be considered in patients undergoing major abdominal or pelvic surgery for cancer with high-risk features (eg, limited mobility, obesity, VTE history, comorbid conditions) (Lyman 2013; Lyman 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Orthopedic surgery:</i> Minimum duration of therapy of 10 to 14 days for patients undergoing total hip arthroplasty, total knee arthroplasty, or hip fracture surgery (ACCP [Guyatt 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Venous thromboembolism (DVT/PE), treatment (off-label dosing):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Initial anticoagulation: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Inpatient setting: 80 units/kg (or alternatively 5,000 units) IV bolus followed by an initial continuous infusion of 18 units/kg/hour (or alternatively 1,000 units/hour) (Guyatt 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">SubQ: Unmonitored dosing regimen (alternative method; <i>not</i> routine): Initial: 333 units/kg, followed by 250 units/kg every 12 hours (Guyatt 2012; Holbrook 2012; Lip 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Long-term (maintenance) anticoagulation: </i>\n      <b>Note:</b> Unfractionated heparin is not a recommended option for long-term (maintenance) anticoagulation (has not been adequately studied); alternative agents are preferred (eg, direct oral anticoagulants, warfarin, low molecular weight heparin [LMWH]) (Hull 2017; Kearon 2012; Kearon 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178776\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=heparin-unfractionated-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Heparin (unfractionated): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Many concentrations of heparin are available ranging from 1 unit/mL to 20,000 units/mL. Carefully examine each prefilled syringe or vial prior to use ensuring that the correct concentration is chosen. Heparin lock flush solution is intended only to maintain patency of IV devices and is not to be used for anticoagulant therapy. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Thrombosis, treatment: </b> <i>Systemic heparinization:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants: IV: Initial loading dose: 75 units/kg over 10 minutes; then initial continuous maintenance infusion at: 28 units/kg/hour; adjust dose to maintain an anti-Xa activity of 0.35 to 0.7 units/mL or an aPTT range that correlates to this anti-Xa range or a protamine titration range of 0.2 to 0.4 units/mL (ACCP [Monagle 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adolescents: IV: Initial loading dose: 75 units/kg over 10 minutes, then initial continuous maintenance infusion at: 20 units/kg/hour; adjust dose to maintain an anti-Xa activity of 0.35 to 0.7 units/mL or an aPTT range that correlates to this anti-Xa range or a protamine titration range of 0.2 to 0.4 units/mL (ACCP [Monagle 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Note:</b> Because of variation among hospitals with reagents (lot numbers) and corresponding control of aPTT values, individual institutions should establish unique, institution-specific nomograms. Due to extensive variability within reagents and anti-Xa levels with corresponding aPTTs, a specific nomogram has not been provided; refer to guidelines for a specific nomogram (ACCP [Monagle 2012]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178758\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Patients &gt;60 years of age may have higher serum levels and clinical response (longer aPTTs) as compared to younger patients receiving similar dosages. Lower dosages may be required.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11256164\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">No dosage adjustment required; adjust therapeutic heparin according to aPTT or anti-Xa activity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Not dialyzable (NCS/SCCM [Frontera 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11256165\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment required; adjust therapeutic heparin according to aPTT or anti-Xa activity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178727\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25,000 units/500 mL in NaCl 0.9% (500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1000 units (500 mL); 2000 units (1000 mL); 12,500 units (250 mL); 25,000 units (250 mL, 500 mL); 1000 units/mL (1 mL, 10 mL, 30 mL); 2500 units/mL (10 mL [DSC]); 5000 units/mL (1 mL, 10 mL); 10,000 units/mL (1 mL, 4 mL, 5 mL); 20,000 units/mL (1 mL); 1000 units (500 mL); 2000 units (1000 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sodium [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1000 units/mL (2 mL); 5000 units/0.5 mL (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hep Flush-10: 10 units/mL (10 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10,000 units (250 mL); 12,500 units (250 mL [DSC]); 20,000 units (500 mL); 25,000 units (250 mL, 500 mL); 1 units/mL (1 mL, 2 mL, 2.5 mL, 3 mL, 5 mL, 10 mL); 2 units/mL (3 mL [DSC]); 10 units/mL (1 mL, 2 mL, 2.5 mL, 3 mL, 5 mL, 10 mL, 30 mL [DSC]); 100 units/mL (1 mL, 2 mL, 2.5 mL, 3 mL, 5 mL, 10 mL, 30 mL [DSC]); 2000 units/mL (5 mL [DSC]); 100 units/100 mL in NaCl 0.45% (100 mL); 1000 units/L in NaCl 0.9% (1000 mL); 15,000 units/500 mL in NaCl 0.9% (500 mL); 2000 units/500 mL in NaCl 0.9% (500 mL); 25,000 units/250 mL in Dextrose 5% (250 mL); 25,000 units/250 mL in NaCl 0.9% (250 mL); 25,000 units/500 mL in Dextrose 5% (500 mL); 250 units/250 mL in NaCl 0.45% (250 mL); 30,000 units/1000 mL in NaCl 0.9% (1000 mL); 4000 units/1000 mL in NaCl 0.9% (1000 mL); 500 units/250 mL in NaCl 0.45% (250 mL); 5000 units/500 mL in NaCl 0.9% (500 mL); 6000 units/1000 mL in NaCl 0.9% (1000 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sodium [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 units/mL (3 mL [DSC]); 10 units/mL (1 mL, 3 mL, 5 mL); 100 units/mL (1 mL, 3 mL, 5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10,000 units/10 mL (10 mL); 20 units/20 mL in NaCl 0.9% (20 mL); 3000 units/3 mL (3 mL); 50 units/50 mL in NaCl 0.45% (50 mL); 5000 units/5 mL (5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178711\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178732\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ: Inject in subcutaneous tissue only (not muscle tissue). Injection sites should be rotated (usually left and right portions of the abdomen, above iliac crest).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">IM: Do not administer IM due to pain, irritation, and hematoma formation. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Continuous IV infusion: Infuse via infusion pump. If preparing solution, mix thoroughly prior to administration. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Heparin lock: Inject via injection cap using positive pressure flushing technique. Heparin lock flush solution is intended only to maintain patency of IV devices and is <b>not</b> to be used for anticoagulant therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Central venous catheters: Must be flushed with heparin solution when newly inserted, daily (at the time of tubing change), after blood withdrawal or transfusion, and after an intermittent infusion through an injectable cap. A volume of at least 10 mL of blood should be removed and discarded from a heparinized line before blood samples are sent for coagulation testing. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Intravesical (off-label use): Various dosage regimens of heparin (20,000 to 50,000 units) alone or with alkalinized lidocaine (1% to 4%) have been instilled into the bladder.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472657\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premixed solutions available</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV infusion:</b> 25,000 units in 250 mL (concentration: 100 units/mL) of D<sub>5</sub>W,   <sup>1</sup>/<sub>2</sub>NS, or NS  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472658\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premixed solutions available</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV infusion:</b> 100 units/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178731\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anticoagulation:</b> Prophylaxis and treatment of thromboembolic disorders (eg, venous thromboembolism, pulmonary embolism) and thromboembolic complications associated with atrial fibrillation; prevention of clotting in arterial and cardiac surgery; as an anticoagulant for extracorporeal circulation and dialysis procedures</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Note:</b> Heparin lock flush solution is intended only to maintain patency of IV devices and is <b>not</b> to be used for systemic anticoagulant therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25483758\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Anticoagulant during percutaneous coronary intervention (PCI); Interstitial cystitis (bladder pain syndrome); Non&ndash;ST-elevation acute coronary syndrome; ST-elevation myocardial infarction (adjunct to fibrinolysis); Valvular heart disease, bridge during oral anticoagulation interruption; According to the antithrombotic guidelines from the American College of Chest Physicians (ACCP), heparin is recommended as an anticoagulant in several conditions in addition to those above, such as the following: Superficial vein thrombosis, patients with atrial fibrillation undergoing cardioversion, nonbacterial thrombotic endocarditis and systemic or pulmonary emboli, cerebral venous sinus thrombosis, and acute arterial emboli or thrombosis. See the ACCP antithrombotic guidelines for more details.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178805\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Heparin may be confused with Hespan</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">National Patient Safety Goals:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Joint Commission (TJC) requires healthcare organizations that provide anticoagulant therapy to have a process in place to reduce the risk of anticoagulant-associated patient harm. Patients receiving anticoagulants should receive individualized care through a defined process that includes standardized ordering, dispensing, administration, monitoring and education. This does not apply to routine short-term use of anticoagulants for prevention of venous thromboembolism when the expectation is that the patient&rsquo;s laboratory values will remain within or close to normal values (NPSG.03.05.01).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The 100 unit/mL concentration should not be used to flush heparin locks, IV lines, or intra-arterial lines in neonates or infants &lt;10 kg (systemic anticoagulation may occur). The 10 unit/mL flush concentration may inadvertently cause systemic anticoagulation in infants &lt;1 kg who receive frequent flushes.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Heparin sodium injection 10,000 units/mL and  Hep-Lock U/P 10 units/mL have been confused with each other. Fatal medication errors have occurred between the two whose labels are both blue. <b>Never rely on color as a sole indicator to differentiate product identity.</b></p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Labeling changes: Effective May 1st, 2013, heparin labeling is required to include the total amount of heparin per vial (rather than only including the amount of heparin per mL). During the transition, hospitals should consider only stocking the newly labeled heparin to avoid potential errors and confusion with the older labeling. </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Heparin lock flush solution is intended only to maintain patency of IV devices and is <b>not</b> to be used for anticoagulant therapy.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178718\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Frequency not defined. Thrombocytopenia has been reported to occur at an incidence between 0% and 30%. It is often of no clinical significance. However, immunologically mediated heparin-induced thrombocytopenia (HIT) has been estimated to occur in 1% to 2% of patients, and is marked by a progressive fall in platelet counts and, in some cases, thromboembolic complications (skin necrosis, pulmonary embolism, gangrene of the extremities, cerebrovascular accident, or myocardial infarction).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest pain, shock (including hemorrhagic shock), thrombosis, vasospasm (allergic; possibly related to thrombosis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, dysesthesia (feet), headache, peripheral neuropathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Dermal ulcer (rarely reported with deep subcutaneous injections; intramuscular injection [not recommended] is associated with a higher incidence of this effect), eczema, erythematous plaques (case reports), localized erythema (rarely reported with deep subcutaneous injections; intramuscular injection [not recommended] is associated with a higher incidence of this effect), skin necrosis, transient alopecia (delayed), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Adrenal hemorrhage, hyperkalemia (suppression of aldosterone synthesis), hyperlipidemia (rebound; on discontinuation), ovarian hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Constipation, hematemesis, melena, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Erectile dysfunction (frequent or persistent erection), hematuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Bruise (unexplained), gingival hemorrhage, hematoma (rarely reported with deep subcutaneous injections; intramuscular injection [not recommended] is associated with a higher incidence of this effect), hemorrhage, pulmonary hemorrhage, purpura, retroperitoneal hemorrhage, thrombocytopenia (see note)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased liver enzymes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactoid reaction, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Local irritation, local pain (rarely reported with deep subcutaneous injections; intramuscular injection [not recommended] is associated with a high incidence of these effects)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Osteoporosis (chronic therapy effect)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Allergic conjunctivitis, lacrimation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Asthma, bronchospasm (case reports), epistaxis, hemoptysis, rhinitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Drug tolerance, fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178735\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to heparin or any component of the formulation (unless a life-threatening situation necessitates use and use of an alternative anticoagulant is not possible); severe thrombocytopenia; history of heparin-induced thrombocytopenia (HIT); uncontrolled active bleeding except when due to disseminated intravascular coagulation (DIC); cases where the administration of sodium or chloride could be clinically detrimental (applies to large volume heparin 2 unit/mL IV solutions only); not for use when appropriate blood coagulation tests cannot be obtained at appropriate intervals (applies to full-dose heparin only).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Note:</b> Some products contain benzyl alcohol as a preservative; their use in neonates, infants, or pregnant or breast-feeding mothers is contraindicated by some manufacturers.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178715\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: May occur, including fatal events. Use with caution in patients with an increased risk of bleeding, including subacute bacterial endocarditis; congenital or acquired bleeding disorders; active ulcerative or angiodysplastic GI diseases; continuous GI tube drainage; severe uncontrolled hypertension; history of hemorrhagic stroke; use shortly after brain, spinal, or ophthalmologic surgery or other invasive procedures including spinal tap or spinal anesthesia; concomitant treatment with platelet inhibitors; recent GI bleeding; impaired hemostasis; thrombocytopenia or platelet defects; patients with hereditary antithrombin deficiency receiving concurrent antithrombin replacement therapy; severe liver disease; hypertensive or diabetic retinopathy; renal failure; or in patients (especially women) &gt;60 years of age. Monitor patient closely for signs or symptoms of bleeding. Discontinue if bleeding occurs; severe hemorrhage or overdosage may require protamine (consult Protamine monograph for dosing recommendations).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heparin resistance: Dose requirements &gt;35,000 units/24 hours to maintain a therapeutic aPTT may occur in patients with antithrombin deficiency, increased heparin clearance, elevations in heparin-binding proteins, elevations in factor VIII and/or fibrinogen; frequently encountered in patients with fever, thrombosis, thrombophlebitis, infections with thrombosing tendencies, MI, cancer, and in postsurgical patients; measurement of anticoagulant effects using antifactor Xa levels may be of benefit.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: Monitor for hyperkalemia; can cause hyperkalemia by suppressing aldosterone production.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: May occur; only in life-threatening situations when use of an alternative anticoagulant is not possible should heparin be cautiously used in patients with a documented hypersensitivity reaction. Some products are derived from animal tissue and may be contraindicated in patients with animal allergies (ie, pork); consult individual prescribing information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteoporosis: May occur with prolonged use (&gt;6 months) due to a reduction in bone mineral density.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombocytopenia: May occur. Heparin-induced thrombocytopenia (HIT), a serious antibody-mediated reaction resulting from irreversible aggregation of platelets, may also occur. Patients who develop HIT may be at risk of developing a new thrombus (heparin-induced thrombocytopenia and thrombosis [HITT]). Monitor platelets closely; discontinue therapy and consider alternatives if platelets are &lt;100,000/mm<sup>3</sup> and/or thrombosis develops. HIT or HITT may be delayed and can occur up to several weeks after discontinuation of heparin. Use with extreme caution (for a limited duration) or avoid in patients with history of HIT, especially if administered within 100 days of HIT episode (Dager 2007; Warkentin 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in patients &gt;60 years of age, particularly women; older adults can be more sensitive to heparin and a higher incidence of bleeding has been reported in these patients. May require lower doses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol as a preservative. In neonates, large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&quot;gasping syndrome&quot;); the &quot;gasping syndrome&quot; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling. Use in neonates, infants, or pregnant or nursing mothers is contraindicated by some manufacturers; the use of preservative-free heparin is, therefore, recommended in these populations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfites: Some preparations contain sulfite which may cause allergic reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fatal medications errors: Many concentrations of heparin are available ranging from 1 unit/mL to 20,000 units/mL. Clinicians <b>must</b> carefully examine each prefilled syringe or vial prior to use ensuring that the correct concentration is chosen; fatal hemorrhages have occurred related to heparin overdose especially in pediatric patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299438\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178720\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8518&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">5-Aminosalicylic Acid Derivatives: May enhance the adverse/toxic effect of Heparin. Specifically, the risk for bleeding/bruising may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: Heparin may enhance the hyperkalemic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: Heparin may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Heparin may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antithrombin: May enhance the anticoagulant effect of Heparin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aspirin: May enhance the anticoagulant effect of Heparin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canagliflozin: Heparin may enhance the hyperkalemic effect of Canagliflozin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Heparin may enhance the adverse/toxic effect of Corticorelin. Significant hypotension and bradycardia have been previously attributed to this combination. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desirudin: Anticoagulants may enhance the anticoagulant effect of Desirudin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another.  See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: Heparin may enhance the hyperkalemic effect of Eplerenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of estrogens against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<b> Exceptions: </b>Tibolone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Factor X (Human): Anticoagulants (Inhibitors of Factor Xa) may diminish the therapeutic effect of Factor X (Human). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: May diminish the anticoagulant effect of Heparin. Nitroglycerin may decrease the serum concentration of Heparin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oritavancin: May diminish the therapeutic effect of Heparin. Specifically, oritavancin may artificially increase the results of laboratory tests commonly used to monitor IV heparin effectiveness, which could lead to incorrect decisions to decrease heparin doses.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: Heparin may increase the serum concentration of Palifermin.  Management: If heparin is used to maintain an intravenous line, rinse the line with saline prior to and after palifermin administration.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the anticoagulant effect of Heparin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Salts: Heparin may enhance the hyperkalemic effect of Potassium Salts. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: Heparin may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.  Management: Monitor serum potassium concentrations closely. The spironolactone Canadian product monograph lists its combination with heparin or low molecular weight heparins as contraindicated.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins: May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Streptokinase: May enhance the anticoagulant effect of Heparin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telavancin: May diminish the therapeutic effect of Heparin. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor IV heparin effectiveness, which could lead to incorrect decisions to decrease heparin doses.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178723\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6481836\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Increased resorptions were observed in some animal reproduction studies. Heparin does not cross the placenta. Heparin may be used for the prevention and treatment of thromboembolism in pregnant women; however the use of low molecular weight heparin (LMWH) is preferred. Twice-daily heparin should be discontinued prior to induction of labor or a planned cesarean delivery. In pregnant women with mechanical heart valves, adjusted-dose LMWH or adjusted-dose heparin may be used throughout pregnancy or until week 13 of gestation when therapy can be changed to warfarin. LMWH or heparin should be resumed close to delivery. In women who are at a very high risk for thromboembolism (older generation prosthesis in mitral position or history of thromboembolism), warfarin can be used throughout pregnancy and replaced with LMWH or heparin near term; the use of low-dose aspirin is also recommended. When choosing therapy, fetal outcomes (ie, pregnancy loss, malformations), maternal outcomes (ie, VTE, hemorrhage), burden of therapy, and maternal preference should be considered (Guyatt 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some products contain benzyl alcohol as a preservative; their use in pregnant women is contraindicated by some manufacturers; use of a preservative free formulation is recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11443865\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Heparin is not excreted into breast milk and can be used in breast-feeding women (Guyatt, 2012). Some products contain benzyl alcohol as a preservative; their use in breast-feeding women is contraindicated by some manufacturers due to the association of gasping syndrome in premature infants.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178725\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hemoglobin, hematocrit, signs of bleeding; fecal occult blood test; aPTT (or antifactor Xa activity levels) or ACT depending upon indication </p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">Platelet counts should be routinely monitored (eg, every 2-3 days on days 4-14 of heparin therapy) when the risk of HIT is &gt;1% (eg, receiving therapeutic dose heparin, postoperative antithrombotic prophylaxis), if the patient has received heparin or low molecular weight heparin (eg, enoxaparin) within the past 100 days, if pre-exposure history is uncertain, or if anaphylactoid reaction to heparin occurs. When the risk of HIT is &lt;1% (eg, medical/obstetrical patients receiving heparin flushes), routine platelet count monitoring is not recommended (Guyatt, 2012). </p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">For intermittent IV injections, aPTT is measured 3.5-4 hours after IV injection.</p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">\n      <b>Note:</b> Continuous IV infusion is preferred over IV intermittent injections. For full-dose heparin (ie, nonlow-dose), the dose should be titrated according to aPTT results. For anticoagulation, an aPTT 1.5-2.5 times normal is usually desired. Because of variation among hospitals in the control aPTT values, nomograms should be established at each institution, designed to achieve aPTT values in the target range (eg, for a control aPTT of 30 seconds, the target range [1.5-2.5 times control] would be 45-75 seconds). Measurements should be made prior to heparin therapy, 6 hours (pediatric: 4 hours) after initiation, and 6 hours (pediatric: 4 hours) after any dosage change, and should be used to adjust the heparin infusion until the aPTT exhibits a therapeutic level. When two consecutive aPTT values are therapeutic, subsequent  measurements may be made every 24 hours, and if necessary, dose adjustment carried out. In addition, a significant change in the patient's clinical condition (eg, recurrent ischemia, bleeding, hypotension) should prompt an immediate aPTT determination, followed by dose adjustment if necessary. In general, may increase or decrease infusion by 2-4 units/kg/hour dependent upon aPTT. </p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">Heparin infusion dose adjustment: A number of dose-adjustment nomograms have been developed which target an aPTT range of 1.5-2.5 times control (Cruickshank, 1991; Flaker, 1994; Hull, 1992; Raschke, 1993). However, institution-specific and indication-specific nomograms should be consulted for dose adjustment. <b>Note:</b> aPTT values vary throughout the day with maximum values occurring during the night (Decousus, 1985). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178728\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Venous thromboembolism: Heparin: 0.3 to 0.7 unit/mL (children: 0.35 to 0.7 unit/mL) anti-Xa activity (by chromogenic assay) or 0.2 to 0.4 unit/mL (by protamine titration); aPTT: 1.5 to 2.5 times control (usually reflects an aPTT of 60 to 85 seconds) (Garcia, 2012; Monagle, 2012) </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When used with thrombolytic therapy in patients with acute MI, a lower therapeutic range corresponding to an aPTT of 1.5 to 2 times control (or approximately an aPTT of 50 to 70 seconds) is recommended (ACCF/AHA [O&rsquo;Gara, 2013). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178714\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Potentiates the action of antithrombin III and thereby inactivates thrombin (as well as activated coagulation factors IX, X, XI, XII, and plasmin) and prevents the conversion of fibrinogen to fibrin; heparin also stimulates release of lipoprotein lipase (lipoprotein lipase hydrolyzes triglycerides to glycerol and free fatty acids)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178734\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;\">\n      <b>Note:</b> Increased interpatient variability of pharmacokinetic parameters in pediatric patients compared to adults; however, age-related decreases in volume of distribution and clearance with increasing pediatric patient age have been reported (ACCP [Monagle 2012]; McDonald 1981).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Anticoagulation: IV: Immediate; SubQ: ~20 to 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral, rectal: Erratic at best from these routes of administration; SubQ absorption is also erratic, but considered acceptable for prophylactic use</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Premature neonates (data based on single dose of 100 units/kg within 4 hours of birth) (McDonald 1981): Inversely proportional to gestational age</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA 25 to 28 weeks: 81 &plusmn; 41 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA 29 to 32 weeks: 73.3 &plusmn; 24.8 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA 33 to 36 weeks: 57.8 &plusmn; 32.2 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Following a single 75 unit/kg dose: 36.6 &plusmn; 7.4 mL/kg (McDonald 1981)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Complex; thought to occur by depolymerization and desulphation via the reticuloendothelial system primarily in the liver and spleen (ACCP [Garcia 2012]; Dawes 1979; Estes 1980; Kandrotas 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Age-related: Shorter half-life reported in premature neonates compared to adult patients</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Premature neonates GA 25 to 36 weeks (data based on single dose of 100 units/kg within 4 hours of birth): Mean range: 35.5 to 41.6 minutes (McDonald 1981)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dose-dependent: IV bolus: 25 units/kg: 30 minutes (Bjornsson 1982); 100 units/kg: 60 minutes (de Swart 1982); 400 units/kg: 150 minutes (Olsson 1963)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mean: 1.5 hours; Range: 1 to 2 hours; affected by obesity, renal function, malignancy, presence of pulmonary embolism, and infections</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> At therapeutic doses, elimination occurs rapidly via nonrenal mechanisms. With very high doses, renal elimination may play more of a role; however, dosage adjustment remains unnecessary for patients with renal impairment (Kandrotas 1992).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (small amounts as unchanged drug); <b>Note: </b>At therapeutic doses, elimination occurs rapidly via nonrenal mechanisms. With very high doses, renal elimination may play more of a role; however, dosage adjustment remains unnecessary for patients with renal impairment (Kandrotas 1992).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Clearance: Age-related changes; within neonatal population, slower clearance with lower GA; however, when compared to adults, the overall clearance in neonatal and pediatric patients is faster than adults (ACCP [Monagle 2012 ]; McDonald 1981)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2524629\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Heparin (Porcine) in NaCl (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1500UT/150ML 0.9% (150 mL): $23.52</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Heparin (Porcine) in NaCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 unit/mL 0.9% (500 mL): $5.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 unit/mL 0.45% (250 mL): $8.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 unit/mL 0.45% (250 mL): $10.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Heparin (Porcine) in NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100UT/100ML 0.45% (100 mL): $10.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250UT/250ML 0.45% (250 mL): $13.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500UT/250ML 0.45% (250 mL): $14.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000UNIT/L 0.9% (1000 mL): $18.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000UT/500ML 0.9% (500 mL): $15.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4000UNIT/L 0.9% (1000 mL): $21.42</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5000UT/500ML 0.9% (500 mL): $15.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6000UNIT/L 0.9% (1000 mL): $20.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15000UT/500ML 0.9% (500 mL): $21.41</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25000UT/250ML 0.45% (250 mL): $20.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25000UT/250ML 0.9% (250 mL): $19.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25000UT/500ML 0.9% (500 mL): $21.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30000UNIT/L 0.9% (1000 mL): $23.14</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Heparin Lock Flush Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 units/mL (3 mL): $3.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 units/mL (5 mL): $3.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 units/mL (5 mL): $2.47</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Heparin Sod (Porcine) in D5W Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 units/mL (250 mL): $20.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Heparin Sodium (Porcine) Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 units/mL (10 mL): $3.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5000 units/mL (1 mL): $1.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10000 units/mL (1 mL): $2.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20000 units/mL (1 mL): $12.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Heparin Sodium (Porcine) PF Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5000 units/0.5 mL (0.5 mL): $6.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Heparin Sodium Lock Flush Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 units/mL (5 mL): $3.53</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Heparin (Porcine) in NaCl (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20UNT/20ML 0.9% (20 mL): $9.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50UNT/50ML 0.45% (50 mL): $10.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50UNT/50ML 0.9% (50 mL): $10.28</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Heparin Sodium (Porcine) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000UNIT/3ML (3 mL): $5.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5000 unit/5 mL (5 mL): $6.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10000 unit/10 mL (10 mL): $9.05</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F178738\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Agglutek (TW);</li>\n      <li>Anticlot (VN);</li>\n      <li>Caprin (IN);</li>\n      <li>Coaparin (PL);</li>\n      <li>Hemastat (PH);</li>\n      <li>Hemonor (PE);</li>\n      <li>Hepaflex (FI, NO);</li>\n      <li>Heparen (LK);</li>\n      <li>Heparin (AT, BF, BG, BJ, CH, CI, CZ, DE, ET, FI, GB, GH, GM, GN, GR, IL, KE, LR, MA, ML, MR, MU, MW, NE, NG, NO, SC, SD, SE, SL, SN, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Heparin Injection B.P. (AU);</li>\n      <li>Heparin Leo (DK, HK, ID, MY, PH, TW);</li>\n      <li>Heparin Novo (TW);</li>\n      <li>Heparin Sodium B Braun (ID, MY);</li>\n      <li>Heparina (ES);</li>\n      <li>Heparine (BE, NL);</li>\n      <li>Heparine Choay (FR);</li>\n      <li>Heparine Novo (BE, NL);</li>\n      <li>Heprin (PH);</li>\n      <li>Hepsal (MT, SA, SG);</li>\n      <li>Heptin (PH);</li>\n      <li>Hiruderm (HK);</li>\n      <li>Inhepar (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Inviclot (ID);</li>\n      <li>Kabihep (PH);</li>\n      <li>Lioton (RU);</li>\n      <li>Liquemin (DE, IT);</li>\n      <li>Liquemine (BE, TR);</li>\n      <li>Minihep (AE, QA);</li>\n      <li>Monoparin (QA, SA);</li>\n      <li>Multiparin (NZ, PK);</li>\n      <li>Nuparin (PH);</li>\n      <li>Proparin (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Rhoneparina (PY);</li>\n      <li>Thrombophob (DE);</li>\n      <li>Thromboreduct (DE);</li>\n      <li>Unihep (AE, QA);</li>\n      <li>Wellparin (VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>J Am Coll Cardiol.</i> 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/25260718/pubmed\" target=\"_blank\" id=\"25260718\">25260718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andrew M, Marzinotto V, Massicotte P, et al, &ldquo;Heparin Therapy in Pediatric Patients: A Prospective Cohort Study,&rdquo; <i>Pediatr Research</i>, 1994, 35(1):78-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/8134203/pubmed\" target=\"_blank\" id=\"8134203\">8134203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bjornsson T, Wolfram B, Kitchell B. Heparin kinetics determined by three assay methods. <i>Clin Pharmacol Ther</i>. 1982;31(1):104&ndash;113.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/7053298/pubmed\" target=\"_blank\" id=\"7053298\">7053298</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Broderick J, Connolly S, Feldmann E, et al, &ldquo;Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group,&rdquo; Stroke, 2007, 38(6):2001-23. Available at http://stroke.ahajournals.org/cgi/content/short/STROKEAHA.107.18368917478736</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cruickshank MK, Levine MN, Hirsh J, et al, &ldquo;A Standard Heparin Nomogram for the Management of Heparin Therapy,&rdquo; <i>Arch Intern Med</i>, 1991, 151(2):333-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/1789820/pubmed\" target=\"_blank\" id=\"1789820\">1789820</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dager WE and White RH, &ldquo;Pharmacotherapy of Heparin-Induced Thrombocytopenia,&rdquo; <i>Expert Opin Pharmacother</i>, 2003, 4(6):919-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/12783589/pubmed\" target=\"_blank\" id=\"12783589\">12783589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dager WE, Dougherty JA, Nguyen PH, et al, &ldquo;Heparin-Induced Thrombocytopenia: Treatment Options and Special Considerations,&rdquo; <i>Pharmacotherapy</i>, 2007, 27(4):564-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/17381384/pubmed\" target=\"_blank\" id=\"17381384\">17381384</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Decousus HA, Croze M, Levi FA, et al, &ldquo;Circadian Changes in Anticoagulant Effect of Heparin Infused at a Constant Rate,&rdquo; <i>Br Med J (Clin Res Ed)</i>, 1985, 290(6465):341-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/3917812/pubmed\" target=\"_blank\" id=\"3917812\">3917812</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Swart C, Nijmeyer B, Roelofs J, Sixma JJ. Kinetics of intravenously administered heparin in normal humans. <i>Blood</i>. 1982;60(6):1251&ndash;1258.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/7139119/pubmed\" target=\"_blank\" id=\"7139119\">7139119</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flaherty ML, &ldquo;Anticoagulant-Associated Intracerebral Hemorrhage,&rdquo; <i>Semin Neuro</i>, 2010, 30(5):565-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/21207349/pubmed\" target=\"_blank\" id=\"21207349\">21207349</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flaker GC, Bartolozzi J, Davis V, et al, &ldquo;Use of a Standardized Heparin Nomogram to Achieve Therapeutic Anticoagulation after Thrombolytic Therapy in Myocardial Infarction. TIMI 4 investigators. Thrombolysis in Myocardial Infarction,&rdquo; <i>Arch Intern Med</i>, 1994, 154(13):1492-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/8018004/pubmed\" target=\"_blank\" id=\"8018004\">8018004</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Francis JL, Groce JB 3rd, and the Heparin Consensus Group, &ldquo;Challenges in Variation and Response of Unfractionated Heparin,&rdquo; <i>Pharmacotherapy</i>, 2004, 24(8 Pt 2), 108-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/15334856/pubmed\" target=\"_blank\" id=\"15334856\">15334856</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freed MD, Keane JF, and Rosenthal A, &ldquo;The Use of Heparinization to Prevent Arterial Thrombosis After Percutaneous Cardiac Catheterization in Children,&rdquo; <i>Circulation</i>, 1974, 50(3):565-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/4607271/pubmed\" target=\"_blank\" id=\"4607271\">4607271</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garcia DA, Baglin TP, Weitz JI, et al, &ldquo;Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):24-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/22315264/pubmed\" target=\"_blank\" id=\"22315264\">22315264</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greinacher A, Janssens U, Berg G, et al, &ldquo;Lepirudin (Recombinant Hirudin) for Parenteral Anticoagulation in Patients With Heparin-Induced Thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) Investigators,&rdquo; <i>Circulation</i>, 1999, 100(6):587-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/10441094/pubmed\" target=\"_blank\" id=\"10441094\">10441094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greinacher A, Volpel H, Janssens U, et al, &ldquo;Recombinant Hirudin (Lepirudin) Provides Safe and Effective Anticoagulation in Patients With Heparin-Induced Thrombocytopenia: A Prospective Study,&rdquo; <i>Circulation</i>, 1999, 99(1):73-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/9884382/pubmed\" target=\"_blank\" id=\"9884382\">9884382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heparin sodium in 0.45% sodium chloride [prescribing information]. Lake Forest, IL: Hospira; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heparin sodium in 0.9% sodium chloride [prescribing information]. Lake Forest, IL: Hospira; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holbrook A, Schulman S, Witt, DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2 suppl):e152S-e184S. doi: 10.1378/chest.11-2295.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/22315259/pubmed\" target=\"_blank\" id=\"22315259\">22315259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hull RD, Lip GYH. Venous thromboembolism: Anticoagulation after initial management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 29, 2018.22315259</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hull RD, Raskob GE, Rosenbloom D, et al, &ldquo;Optimal Therapeutic Level of Heparin Therapy in Patients with Venous Thromboembolism,&rdquo; <i>Arch Intern Med</i>, 1992, 152(8):1589-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/1497392/pubmed\" target=\"_blank\" id=\"1497392\">1497392</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, &ldquo;Standard Concentrations of Neonatal Drug Infusions,&rdquo; 2011. Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jaff MR, McMurtry MS, Archer SL, et al, &ldquo;Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: A Scientific Statement from the American Heart Association,&rdquo; <i>Circulation</i>, 2011, 123(16):1788-830.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/21422387/pubmed\" target=\"_blank\" id=\"21422387\">21422387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. <i>Clin Pharmacokinet</i>. 1992;22(5):359-374.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/1505142/pubmed\" target=\"_blank\" id=\"1505142\">1505142</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [published correction appears in <i>Chest</i>. 2012;142(6):1698-1704]. <i>Chest</i>. 2012;141(2)(suppl):e419S-e496S. doi: 10.1378/chest.11-2301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/22315268/pubmed\" target=\"_blank\" id=\"22315268\">22315268</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE disease: CHEST guideline and expert panel report. <i>Chest</i>. 2016;149(2):315-352. doi: 10.1016/j.chest.2015.11.026.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/26867832/pubmed\" target=\"_blank\" id=\"26867832\">26867832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kincaid EH, Hammon JW. Cardiopulmonary Bypass. In: Yuh DD, Vricella LA, Yang SC, Doty JR. eds. <i>Johns Hopkins Textbook of Cardiothoracic Surgery, Second Edition. </i>New York, NY: McGraw-Hill; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klerk CP, Smorenburg SM, and Buller HR, &ldquo;Thrombosis Prophylaxis in Patient Populations With a Central Venous Catheter: A Systematic Review,&rdquo; <i>Arch Intern Med</i>, 2003, 163(16):1913-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/12963564/pubmed\" target=\"_blank\" id=\"12963564\">12963564</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuo HC. Urodynamic results of intravesical heparin therapy for women with frequency urgency syndrome and interstitial cystitis. <i>J Formos Med Assoc</i>. 2001;100(5):309-314.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/11432309/pubmed\" target=\"_blank\" id=\"11432309\">11432309</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo; <i>Circulation</i>, 2011, 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lip GYH, Hull RD. Venous thromboembolism: Initiation of anticoagulation (first 10 days). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 29, 2018.22064601</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyman GH, Bohlke K, Khorana AA, et al; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. <i>J Clin Oncol</i>. 2015;33(6):654-656. doi: 10.1200/JCO.2014.59.7351.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/25605844/pubmed\" target=\"_blank\" id=\"25605844\">25605844</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyman GH, Khorana AA, Kuderer NM, et al; American Society of Clinical Oncology Clinical Practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2013;31(17):2189-2204. doi: 10.1200/JCO.2013.49.1118.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/23669224/pubmed\" target=\"_blank\" id=\"23669224\">23669224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McDonald MM, Jacobson LJ, Hay WW Jr, Hathaway WE. Heparin clearance in the newborn. <i>Pediatr Res</i>. 1981;15(7):1015-1018.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/7254945/pubmed\" target=\"_blank\" id=\"7254945\">7254945</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Monagle P, Chan A, Goldenberg NA, et al, &quot;Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition),&quot; <i>Chest</i>, 2012, 141(2 Suppl):e737-801.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/22315277/pubmed\" target=\"_blank\" id=\"22315277\">22315277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morimoto Y, Niwa H, Minematsu K. Risk factors affecting hemorrhage after tooth extraction in patients undergoing continuous infusion with unfractionated heparin. <i>J Oral Maxillofac Surg</i>. 2012;70(3):521-526.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/22177816/pubmed\" target=\"_blank\" id=\"22177816\">22177816</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2017;70(2):252-289.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/28315732/pubmed\" target=\"_blank\" id=\"28315732\">28315732</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nomiya A, Naruse T, Niimi A, et al. On- and post-treatment symptom relief by repeated instillations of heparin and alkalized lidocaine in interstitial cystitis. <i>Int J Urol</i>. 2013;20(11):1118-1122.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/23432185/pubmed\" target=\"_blank\" id=\"23432185\">23432185</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23247304\"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481.] <i>Circulation</i>. 2013;127(4):e362-e425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Olsson P, Lagergren H, Ek S. The elimination from plasma of intravenous heparin: An experimental study on dogs and humans. <i>Acta Med Scand</i>. 1963;173:619&ndash;630.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/13940090/pubmed\" target=\"_blank\" id=\"13940090\">13940090</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parsons CL, Zupkas P, Proctor J, et al. Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis. <i>J Sex Med</i>. 2012;9(1):207-212.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/22082303/pubmed\" target=\"_blank\" id=\"22082303\">22082303</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pasquale LD, Ferneini EM. Heparin and Lovenox: What the Oral and Maxillofacial Surgeon Needs to Know. <i>Oral Maxillofac Surg Clin North Am</i>. 2016;28(4):507-513.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/27624773/pubmed\" target=\"_blank\" id=\"27624773\">27624773</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo; <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8214998\"></a>Raschke RA, Reilly BM, Guidry JR, et al, &ldquo;The Weight-Based Heparin Dosing Nomogram Compared With a &ldquo;Standard Care&rdquo; Nomogram: A Randomized Controlled Trial,&rdquo; <i>Ann Intern Med</i>, 1993, 119(9):874-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/8214998/pubmed\" target=\"_blank\" id=\"8214998\">8214998</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Savi P, Chong BH, Greinacher A, et al, &ldquo;Effect of Fondaparinux on Platelet Activation in the Presence of Heparin-Dependent Antibodies: A Blinded Comparative Multicenter Study With Unfractionated Heparin,&rdquo; <i>Blood</i>, 2005, 105(1):139-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/15388575/pubmed\" target=\"_blank\" id=\"15388575\">15388575</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15199346\"></a>Sinnaeve PR, Alexander JH, Bogaerts K, et al,&ldquo;Efficacy of Tenecteplase in Combination With Enoxaparin, Abciximab, or Unfractionated Heparin: One-Year Follow-Up Results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) Randomized Trial in Acute Myocardial Infarction,&rdquo; <i>Am Heart J</i>, 2004, 147(6):993-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/15199346/pubmed\" target=\"_blank\" id=\"15199346\">15199346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Verma AK, Levine M, Shalansky SJ, et al, &ldquo;Frequency of Heparin-Induced Thrombocytopenia in Critical Care Patients,&rdquo; <i>Pharmacotherapy</i>, 2003, 23(6):745-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/12820817/pubmed\" target=\"_blank\" id=\"12820817\">12820817</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wada H, Thachil J, Di Nisio M, Mathew P, et al. The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. <i>J Thromb Haemost. </i>2013 [Epub ahead of print].<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/23379279/pubmed\" target=\"_blank\" id=\"23379279\">23379279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warkentin TE and Kelton JG, &ldquo;Temporal Aspects of Heparin-Induced Thrombocytopenia,&rdquo; <i>N Engl J Med</i>, 2001, 344(17):1286-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/11320387/pubmed\" target=\"_blank\" id=\"11320387\">11320387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warkentin TE, &quot;Heparin-Induced Thrombocytopenia: A Clinicopathologic Syndrome,&quot; <i>Thromb Haemost</i>, 1999, 82(2):439-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/10605735/pubmed\" target=\"_blank\" id=\"10605735\">10605735</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warkentin TE, Levine MN, Hirsch J, et al, &ldquo;Heparin-Induced Thrombocytopenia in Patients Treated With Low-Molecular Weight Heparin or Unfractionated Heparin,&rdquo; <i>N Engl J Med</i>, 1995, 332(20):1330-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/7715641/pubmed\" target=\"_blank\" id=\"7715641\">7715641</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    You JJ, Singer DE, Howard PA, et al; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i>. 2012;141(2 suppl):e531S-e575S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/heparin-unfractionated-drug-information/abstract-text/22315271/pubmed\" target=\"_blank\" id=\"22315271\">22315271</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8518 Version 239.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F178752\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F178753\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F178797\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F178757\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F178776\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F178758\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F11256164\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F11256165\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F178727\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F178711\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F178732\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14472657\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14472658\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F178731\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25483758\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F178805\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F178718\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F178735\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F178715\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299438\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F178720\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F178723\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6481836\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F11443865\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F178725\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F178728\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F178714\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F178734\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F2524629\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F178738\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8518|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=heparin-unfractionated-patient-drug-information\" class=\"drug drug_patient\">Heparin (unfractionated): Patient drug information</a></li><li><a href=\"topic.htm?path=heparin-unfractionated-pediatric-drug-information\" class=\"drug drug_pediatric\">Heparin (unfractionated): Pediatric drug information</a></li></ul></div></div>","javascript":null}